Cargando…

A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population

BACKGROUND AND OBJECTIVE: While the current landscape of opioid use disorder (OUD) is complicated by the increase in use of non-prescription opioids, prescription opioids continue to be frequently used in non-medical ways. In response to this abuse, pharmaceutical companies have developed abuse dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Jewell, Jennifer, Black, Joshua, Ellis, Matthew, Olsen, Heather, Iwanicki, Janetta, Dart, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049928/
https://www.ncbi.nlm.nih.gov/pubmed/36859697
http://dx.doi.org/10.1007/s40261-023-01248-9
_version_ 1785014569349939200
author Jewell, Jennifer
Black, Joshua
Ellis, Matthew
Olsen, Heather
Iwanicki, Janetta
Dart, Richard
author_facet Jewell, Jennifer
Black, Joshua
Ellis, Matthew
Olsen, Heather
Iwanicki, Janetta
Dart, Richard
author_sort Jewell, Jennifer
collection PubMed
description BACKGROUND AND OBJECTIVE: While the current landscape of opioid use disorder (OUD) is complicated by the increase in use of non-prescription opioids, prescription opioids continue to be frequently used in non-medical ways. In response to this abuse, pharmaceutical companies have developed abuse deterrent formulations (ADFs) for extended-release (ER) opioids. To test the effectiveness of Xtampza ER ADF (oxycodone myristate) at reducing tampering, its rate of tampering in a treatment-center population was compared to immediate release (IR) single entity (SE) oxycodone, other ER oxycodone opioids, and ER oxymorphone. METHODS: Data were collected between the third quarter of 2018 and the third quarter of 2021 from individuals entering nationally distributed opioid treatment programs. To determine odds of tampering with Xtampza ER compared to each comparator, a logistic model was fit with a random intercept allowing for multiple drugs in each subject. Within-subject correlation was assumed to have a compound symmetric relationship. RESULTS: Overlap among the categories of drug tampering was high. Logistic regression analyses found that oxycodone myristate had lower odds of tampering when compared to both IR SE oxycodone (OR = 0.23 [95% CI 0.11, 0.50], p = 0.0002) and ER oxymorphone (OR = 0.30 [95% CI 0.14, 0.67], p = 0.0038). Oxycodone myristate was not significantly different from other ER oxycodone opioids (OR = 0.5 [95% CI 0.24, 1.03], p = 0.0612). These findings did not change when the estimates were adjusted for age and sex. CONCLUSIONS: Drugs employing ADF technology may reduce the likelihood of tampering when compared to non-ADF formulations in a treatment-center population, which represents an opportunity for intervention in OUD among those still requiring pain management. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40261-023-01248-9.
format Online
Article
Text
id pubmed-10049928
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-100499282023-03-30 A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population Jewell, Jennifer Black, Joshua Ellis, Matthew Olsen, Heather Iwanicki, Janetta Dart, Richard Clin Drug Investig Original Research Article BACKGROUND AND OBJECTIVE: While the current landscape of opioid use disorder (OUD) is complicated by the increase in use of non-prescription opioids, prescription opioids continue to be frequently used in non-medical ways. In response to this abuse, pharmaceutical companies have developed abuse deterrent formulations (ADFs) for extended-release (ER) opioids. To test the effectiveness of Xtampza ER ADF (oxycodone myristate) at reducing tampering, its rate of tampering in a treatment-center population was compared to immediate release (IR) single entity (SE) oxycodone, other ER oxycodone opioids, and ER oxymorphone. METHODS: Data were collected between the third quarter of 2018 and the third quarter of 2021 from individuals entering nationally distributed opioid treatment programs. To determine odds of tampering with Xtampza ER compared to each comparator, a logistic model was fit with a random intercept allowing for multiple drugs in each subject. Within-subject correlation was assumed to have a compound symmetric relationship. RESULTS: Overlap among the categories of drug tampering was high. Logistic regression analyses found that oxycodone myristate had lower odds of tampering when compared to both IR SE oxycodone (OR = 0.23 [95% CI 0.11, 0.50], p = 0.0002) and ER oxymorphone (OR = 0.30 [95% CI 0.14, 0.67], p = 0.0038). Oxycodone myristate was not significantly different from other ER oxycodone opioids (OR = 0.5 [95% CI 0.24, 1.03], p = 0.0612). These findings did not change when the estimates were adjusted for age and sex. CONCLUSIONS: Drugs employing ADF technology may reduce the likelihood of tampering when compared to non-ADF formulations in a treatment-center population, which represents an opportunity for intervention in OUD among those still requiring pain management. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40261-023-01248-9. Springer International Publishing 2023-03-01 2023 /pmc/articles/PMC10049928/ /pubmed/36859697 http://dx.doi.org/10.1007/s40261-023-01248-9 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Jewell, Jennifer
Black, Joshua
Ellis, Matthew
Olsen, Heather
Iwanicki, Janetta
Dart, Richard
A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
title A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
title_full A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
title_fullStr A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
title_full_unstemmed A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
title_short A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
title_sort cross-sectional study of tampering in xtampza er, an abuse-deterrent formulation of an extended-release opioid, in a treatment center population
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049928/
https://www.ncbi.nlm.nih.gov/pubmed/36859697
http://dx.doi.org/10.1007/s40261-023-01248-9
work_keys_str_mv AT jewelljennifer acrosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT blackjoshua acrosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT ellismatthew acrosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT olsenheather acrosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT iwanickijanetta acrosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT dartrichard acrosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT jewelljennifer crosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT blackjoshua crosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT ellismatthew crosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT olsenheather crosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT iwanickijanetta crosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation
AT dartrichard crosssectionalstudyoftamperinginxtampzaeranabusedeterrentformulationofanextendedreleaseopioidinatreatmentcenterpopulation